Kirsten NÃ¸rgaard

List of Publications by Year
in descending order

167 papers	8,678 citations	76326 40 h-index	48315 88 g-index
181 all docs	181 docs citations	181 times ranked	6911 citing authors

#	Article	IF	Citations
1	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. Journal of Diabetes Science and Technology, 2023, 17, 1226-1242.	2.2	69
2	Can the Use of Continuous Glucose Monitoring Improve Glycemic Control in Patients with Type 1 and 2 Diabetes Receiving Dialysis?. Nephron, 2023, 147, 91-96.	1.8	5
3	Values and control in type 1 diabetes beyond glycemic outcomes: A qualitative interview study of everyday life with an insulin pump. Chronic Illness, 2022, 18, 620-633.	1.5	4
4	Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump–treated type 1 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 212-220.	4.4	4
5	Comparison of treatment with insulin degludec and glargine <scp>U100</scp> in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The <scp>HypoDeg</scp> randomized, controlled, open-label, crossover trial. Diabetes, Obesity and Metabolism, 2022, 24, 257-267.	4.4	6
6	Hemoglobin A1c and Fructosamine Evaluated in Patients with Type 2 Diabetes Receiving Peritoneal Dialysis Using Long-Term Continuous Glucose Monitoring. Nephron, 2022, 146, 146-152.	1.8	4
7	Insulin Pump Treatment in Adults with Type 1 Diabetes in the Capital Region of Denmark: Design and Cohort Characteristics of the Steno Tech Survey. Diabetes Therapy, 2022, 13, 113-129.	2.5	6
8	Glycemic Effects and Predictors of Increased Time-in-Range After Initiating MiniMed 670G: A 12-Month Observational Study. Diabetes Technology and Therapeutics, 2022, 24, 592-597.	4.4	2
9	Continuous Glucose Monitoring-Recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia. Diabetes Technology and Therapeutics, 2022, 24, 643-654.	4.4	6
10	Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover Study. Diabetes Care, 2022, 45, 1391-1399.	8.6	7
11	Glucagon for hypoglycaemia treatment in type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2021, 37, e3409.	4.0	4
12	Education programmes for persons with type 1 diabetes using an insulin pump: A systematic review. Diabetes/Metabolism Research and Reviews, 2021, 37, e3412.	4.0	10
13	Feasibility of a New Approach to Initiate Insulin in Type 2 Diabetes. Journal of Diabetes Science and Technology, 2021, 15, 339-345.	2.2	9
14	The Use of HbA1c, Glycated Albumin and Continuous Glucose Monitoring to Assess Glucose Control in the Chronic Kidney Disease Population Including Dialysis. Nephron, 2021, 145, 14-19.	1.8	21
15	Integrated personalized diabetes management goes Europe: A multi-disciplinary approach to innovating type 2 diabetes care in Europe. Primary Care Diabetes, 2021, 15, 360-364.	1.8	10
16	Achieving a useful and person-centred diabetes consultation is a shared responsibility between diabetologists and people with diabetes: a qualitative study of perspectives from people with type 1 diabetes. Diabetic Medicine, 2021, 38, e14382.	2.3	6
17	The effect of preceding glucose decline rate on low-dose glucagon efficacy in individuals with type 1 diabetes: A randomized crossover trial. Diabetes, Obesity and Metabolism, 2021, 23, 1057-1062.	4.4	0
18	Efficacy of Bolus Calculation and Advanced Carbohydrate Counting in Type 2 Diabetes: A Randomized Clinical Trial. Diabetes Technology and Therapeutics, 2021, 23, 95-103.	4.4	10

#	ARTICLE	IF	CITATIONS
19	Changes in the lipidome in type 1 diabetes following low carbohydrate diet: Post‑hoc analysis of a randomized crossover trial. Endocrinology, Diabetes and Metabolism, 2021, 4, e00213.	2.4	9
20	Real-time continuous glucose monitoring versus self-monitoring of blood glucose in adults with insulin-treated type 2 diabetes: a protocol for a randomised controlled single-centre trial. BMJ Open, 2021, 11, e040648.	1.9	1
21	Glucose management for exercise using continuous glucose monitoring: should sex and prandial state be additional considerations? Reply to Yardley JE and Sigal RJ [letter]. Diabetologia, 2021, 64, 935-938.	6.3	4
22	Advances in Insulin Pump Infusion Sets Symposium Report. Journal of Diabetes Science and Technology, 2021, 15, 705-709.	2.2	10
23	CopenFast trial: Faster-acting insulin Fiasp versus insulin NovoRapid in the treatment of women with type 1 or type 2 diabetes during pregnancy and lactation - a randomised controlled trial. BMJ Open, 2021, 11, e045650.	1.9	5
24	Is reimbursement for alerts and real-time continuous glucose monitoring needed?. Lancet, The, 2021, 397, 2230-2232.	13.7	3
25	Comparison of Glycemic Metrics Measured Simultaneously by Intermittently Scanned Continuous Glucose Monitoring and Real-Time Continuous Glucose Monitoring in Pregnant Women with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2021, 23, 665-672.	4.4	22
26	The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2021, 44, 2589-2625.	8.6	244
27	The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2021, 64, 2609-2652.	6.3	128
28	Flash glucose monitoring and automated bolus calculation in type 1 diabetes treated with multiple daily insulin injections: a 26‑week randomised, controlled, multicentre trial. Diabetologia, 2021, 64, 2713-2724.	6.3	12
29	A New Stochastic Approach for Modeling Glycemic Disturbances in Type 2 Diabetes. IEEE Transactions on Biomedical Engineering, 2021, 68, 3161-3172.	4.2	3
30	Lifestyle Intervention in Pregnant Women With Obesity Impacts Cord Blood DNA Methylation, Which Associates With Body Composition in the Offspring. Diabetes, 2021, 70, 854-866.	0.6	28
31	Parameter Estimation in Type 2 Diabetes in the Presence of Unannounced Meals and Unmodelled Disturbances*. , 2021, , .		0
32	Parameter Estimation for a Jump Diffusion Model of Type 2 Diabetic Patients in the Presence of Unannounced Meals. , 2021, , .		2
33	Glycaemic variability and hypoglycaemia are associated with C-peptide levels in insulin-treated type 2 diabetes. Diabetes and Metabolism, 2020, 46, 61-65.	2.9	21
34	Glucose Sensor Accuracy After Subcutaneous Glucagon Injections Near to Sensor Site. Diabetes Technology and Therapeutics, 2020, 22, 131-135.	4.4	1
35	Insulin Pump Settings During Breastfeeding in Women with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2020, 22, 314-320.	4.4	8
36	Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‑pump‑treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double‑blinded, placebo‑controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 492-500.	4.4	29

#	Article	IF	Citations
37	Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). Diabetologia, 2020, 2501-2520.	6.3	102
38	Glucose management for exercise using continuous glucose monitoring (<scp>CGM</scp>) and intermittently scanned <scp>CGM</scp> (<scp>isCGM</scp>) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (<scp>EASD</scp>) and of the International Society for Pediatric and Adolescent Diabetes (<scp>ISPAD</scp>) endorsed by <scp>. Pediatric Diabetes, 2020, 21, 1375-1393.	2.9	46
39	Effect of adjunctive glucose-lowering drugs on body weight in people with type 1 diabetes: a systematic review and network meta-analysis protocol. BMJ Open, 2020, 10, e038970.	1.9	0
40	Improved Time in Range Over 1 Year Is Associated With Reduced Albuminuria in Individuals With Sensor-Augmented Insulin Pumpâ€"Treated Type 1 Diabetes. Diabetes Care, 2020, 43, 2882-2885.	8.6	49
41	Newborn body composition after maternal bariatric surgery. PLoS ONE, 2020, 15, e0231579.	2.5	3
42	Telemedicine Consultations and Diabetes Technology During COVID-19. Journal of Diabetes Science and Technology, 2020, 14, 767-768.	2.2	33
43	Study protocol for optimising glycaemic control in type 1 diabetes treated with multiple daily insulin injections: intermittently scanned continuous glucose monitoring, carbohydrate counting with automated bolus calculation, or both? A randomised controlled trial. BMJ Open, 2020, 10, e036474.	1.9	4
44	Psychosocial factors associated with HbA 1c in adults with insulin pumpâ€treated type 1 diabetes: a systematic review. Diabetic Medicine, 2020, 37, 1454-1462.	2.3	8
45	28-LB: Improved Time in Glucose Range over One Year Is Associated with Reduced Albuminuria in Sensor-Augmented Insulin Pumpâ€"Treated Type 1 Diabetes. Diabetes, 2020, 69, .	0.6	1
46	1913-P: Rate of Preceding Glucose Fall Does Not Affect the Glucose Response to Low-Dose Glucagon in People with Type 1 Diabetes. Diabetes, 2020, 69, 1913-P.	0.6	0
47	794-P: â€œThe Tool Created a Chance to Discuss Topics You Donâ€™t Normally Address in Diabetes Consultationsâ€: A Study of Using Patient-Reported Outcomes to Promote Person-Centered Care and Psychosocial Support. Diabetes, 2020, 69, 794-P.	0.6	0
48	270-OR: Nocturnal Hypoglycemia with Insulin Degludec and Glargine U100 in Patients with Type 1 Diabetes Prone to Severe Nocturnal Hypoglycemia (HypoDeg): A CGM Substudy. Diabetes, 2020, 69, 270-OR.	0.6	0
49	269-OR: Effect of Insulin Degludec on Frequency of Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia: The HypoDeg Trial. Diabetes, 2020, 69, 269-OR.	0.6	0
50	The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design. BMC Endocrine Disorders, 2019, 19, 78.	2.2	10
51	Preference for Subcutaneously Administered Low-Dose Glucagon Versus Orally Administered Glucose for Treatment of Mild Hypoglycemia: A Prospective Survey Study. Diabetes Therapy, 2019, 10, 2107-2113.	2.5	2
52	Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care, 2019, 42, 1593-1603.	8.6	2,101
53	Use of fastâ€acting insulin aspart in insulin pump therapy in clinical practice. Diabetes, Obesity and Metabolism, 2019, 21, 2039-2047.	4.4	41
54	A Response to â€œThe Relationship Between Sleep and Quality of Life in Type 1 Diabetes Patientsâ€. Diabetes Therapy, 2019, 10, 1173-1174.	2.5	0

#	ARTICLE	IF	CITATIONS
55	Comparison of Continuous Glucose Monitoring Accuracy Between Abdominal and Upper Arm Insertion Sites. Diabetes Technology and Therapeutics, 2019, 21, 295-302.	4.4	25
56	Low versus high carbohydrate diet in type 1 diabetes: A 12â€week randomized openâ€label crossover study. Diabetes, Obesity and Metabolism, 2019, 21, 1680-1688.	4.4	45
57	Skin Problems Due to Treatment with Technology Are Associated with Increased Disease Burden Among Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2019, 21, 215-221.	4.4	20
58	Quality of Life is Markedly Impaired by Rheumatological and Skin Manifestations in Patients with Type 1 Diabetes: A Questionnaire Survey. Diabetes Therapy, 2019, 10, 635-647.	2.5	9
59	Preserved glucose response to low-dose glucagon after exercise in insulin-pump-treated individuals with type 1 diabetes: a randomised crossover study. Diabetologia, 2019, 62, 582-592.	6.3	18
60	2315-PUB: A Priori Classification of Type 2 Diabetes Patients to Determine the Needed Therapy Option. Diabetes, 2019, 68, .	0.6	13
61	Diabetic Ketoacidosis in A Person with Insulin Pump-Treated Type 1 Diabetes Mellitus while Following A Very Low Carbohydrate Diet â€" A Case Report. Archives of Clinical and Medical Case Reports, 2019, 03, .	0.1	2
62	790-P: The Amount of Carbohydrate in the Diet Affects Glucose Dynamics Day and Night. Diabetes, 2019, 68, 790-P.	0.6	0
63	1114-P: Feasibility Study of a Novel Way to Initiate Insulin Treatment in Persons with Type 2 Diabetes. Diabetes, 2019, 68, 1114-P.	0.6	0
64	765-P: Effects of an Advanced Carbohydrate Counting Course on Diet Composition in Insulin-Treated Type 2 Diabetes. Diabetes, 2019, 68, .	0.6	0
65	965-P: Glucose Sensor Accuracy after Subcutaneous Glucagon Injections Near to Sensor Site. Diabetes, 2019, 68, .	0.6	0
66	847-P: Diabetes-Specific Social Capital through Peer Supportâ€"A Study of Facilitators. Diabetes, 2019, 68, .	0.6	1
67	1057-P: Performance Enhancement of Fully Closed-Loop Insulin Delivery in Type 2 Diabetes by Automatized Bolusing. Diabetes, 2019, 68, .	0.6	0
68	Analyzing the Potential of Advanced Insulin Dosing Strategies in Patients With Type 2 Diabetes: Results From a Hybrid In Silico Study. Journal of Diabetes Science and Technology, 2018, 12, 1029-1040.	2.2	5
69	Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis. Diabetes Therapy, 2018, 9, 891-917.	2.5	21
70	Effects of Preceding Ethanol Intake on Glucose Response to Low-Dose Glucagon in Individuals With Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study. Diabetes Care, 2018, 41, 797-806.	8.6	10
71	Effect of Insulin Analogs on Frequency of Nonâ€"Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Severe Hypoglycemia: Much Higher Rates Detected by Continuous Glucose Monitoring than by Self-Monitoring of Blood Glucoseâ€"The HypoAna Trial. Diabetes Technology and Therapeutics, 2018, 20, 247-256.	4.4	17
72	Relationship between Optimum Miniâ€doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes â€" A Simulation Study. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 322-330.	2.5	4

#	ARTICLE	IF	CITATIONS
73	Overnight glucose control in people with type 1 diabetes. Biomedical Signal Processing and Control, 2018, 39, 503-512.	5.7	40
74	Effects of alcohol on plasma glucose and prevention of alcohol–induced hypoglycemia in type 1 diabetes—A systematic review with GRADE. Diabetes/Metabolism Research and Reviews, 2018, 34, e2965.	4.0	47
75	Skin Problems Associated with Insulin Pumps and Sensors in Adults with Type 1 Diabetes: A Cross-Sectional Study. Diabetes Technology and Therapeutics, 2018, 20, 475-482.	4.4	41
76	C-Peptide Levels Are Associated with Glycemic Variability and Hypoglycemia in Insulin-Treated Type 2 Diabetes. Diabetes, 2018, 67, .	0.6	2
77	Prediction of Nonsevere Hypoglycemia—The Influence of Glycemic Variability in the HypoAna Study. Diabetes, 2018, 67, .	0.6	0
78	Adaptive control in an artificial pancreas for people with type 1 diabetes. Control Engineering Practice, 2017, 58, 332-342.	5.5	67
79	Efficacy of basal–bolus insulin regimens in the inpatient management of non–critically ill patients with type 2 diabetes: A systematic review and meta–analysis. Diabetes/Metabolism Research and Reviews, 2017, 33, e2885.	4.0	37
80	Impact of lifestyle intervention for obese women during pregnancy on maternal metabolic and inflammatory markers. International Journal of Obesity, 2017, 41, 598-605.	3.4	39
81	Comparing effects of insulin analogues and human insulin on nocturnal glycaemia in hypoglycaemia–prone people with Type 1 diabetes. Diabetic Medicine, 2017, 34, 625-631.	2.3	14
82	Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2017, 11, 1101-1111.	2.2	14
83	Long-Term Adherence to Automated Bolus Calculators. Journal of Diabetes Science and Technology, 2017, 11, 174-175.	2.2	4
84	Exploring factors influencing HbA1c and psychosocial outcomes in people with type 1 diabetes after training in advanced carbohydrate counting. Diabetes Research and Clinical Practice, 2017, 130, 61-66.	2.8	7
85	Fault and meal detection by redundant continuous glucose monitors and the unscented Kalman filter. Biomedical Signal Processing and Control, 2017, 38, 86-99.	5.7	32
86	Short–term effects of a low carbohydrate diet on glycaemic variables and cardiovascular risk markers in patients with type 1 diabetes: <scp>A</scp> randomized open–label crossover trial. Diabetes, Obesity and Metabolism, 2017, 19, 1479-1484.	4.4	67
87	Evaluation of pharmacokinetic model designs for subcutaneous infusion of insulin aspart. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 477-489.	1.8	3
88	International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care, 2017, 40, 1631-1640.	8.6	1,376
89	Low-Carbohydrate Diet Impairs the Effect of Glucagon in the Treatment of Insulin-Induced Mild Hypoglycemia: A Randomized Crossover Study. Diabetes Care, 2017, 40, 132-135.	8.6	60
90	The potential for improvement of outcomes by personalized insulin treatment of type 1 diabetes as assessed by analysis of single-patient data from a randomized controlled cross-over insulin trial. Diabetes Research and Clinical Practice, 2017, 123, 143-148.	2.8	4

#	Article	IF	Citations
91	Effects of advanced carbohydrate counting guided by an automated bolus calculator in Type 1 diabetes mellitus (Steno‹scp›ABC‹/scp›): a 12‑month, randomized clinical trial. Diabetic Medicine, 2017, 34, 708-715.	2.3	34
92	Sensor-Augmented Insulin Pumps and Hypoglycemia Prevention in Type 1 Diabetes. Journal of Diabetes Science and Technology, 2017, 11, 50-58.	2.2	40
93	An Adaptive Nonlinear Basal-Bolus Calculator for Patients With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2017, 11, 29-36.	2.2	25
94	The effect of peer support in adults with insulin pump-treated type 1 diabetes: a pilot study of a flexible and participatory intervention. Patient Preference and Adherence, 2017, Volume 11, 1879-1890.	1.8	19
95	Effects of subcutaneous, low‑dose glucagon on insulin‑induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 410-418.	4.4	33
96	Insulin Pumps. Diabetes Technology and Therapeutics, 2016, 18, S-22-S-28.	4.4	0
97	Glucose tolerance in obese pregnant women determines newborn fat mass. Acta Obstetricia Et Gynecologica Scandinavica, 2016, 95, 429-435.	2.8	5
98	Retinal characteristics during 1 year of insulin pump therapy in type 1 diabetes: a prospective, controlled, observational study. Acta Ophthalmologica, 2016, 94, 540-547.	1.1	14
99	Application of the continuous-discrete extended Kalman filter for fault detection in continuous glucose monitors for type 1 diabetes. , 2016, , .		8
100	Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with type 1 diabetes prone to severe hypoglycaemia: The HypoAna trial. Diabetes and Metabolism, 2016, 42, 249-255.	2.9	25
101	Comparison of three nonlinear filters for fault detection in continuous glucose monitors. , 2016, 2016, 3507-3510.		5
102	Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia. Current Medical Research and Opinion, 2016, 32, 1719-1725.	1.9	6
103	Cost‑effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in Type 1 diabetes: a systematic review. Diabetic Medicine, 2015, 32, 1415-1424.	2.3	58
104	Intake of Sweets, Snacks and Soft Drinks Predicts Weight Gain in Obese Pregnant Women: Detailed Analysis of the Results of a Randomised Controlled Trial. PLoS ONE, 2015, 10, e0133041.	2.5	47
105	Performance and Acceptability of a Combined Device for Insulin Infusion and Glucose Sensing in the Home Setting. Journal of Diabetes Science and Technology, 2015, 9, 215-220.	2.2	19
106	Use of advanced carbohydrate counting and an automated bolus calculator in clinical practice: the BolusCal‹sup›®‹/sup›training concept. International Diabetes Nursing, 2015, 12, 8-13.	0.1	8
107	The contribution of glucagon in an Artificial Pancreas for people with type 1 diabetes. , 2015, , .		13
108	Bihormonal control of blood glucose in people with type 1 diabetes. , 2015, , .		5

#	Article	IF	Citations
109	Comparison of Prediction Models for a Dual-Hormone Artificial Pancreasâˆ—âˆ——Funded by the Danish Diabetes Academy supported by the Novo Nordisk Foundation. Contact information: John Bagterp J_rgensen(jbjo@dtu.dk).. IFAC-PapersOnLine, 2015, 48, 7-12.	0.9	12
110	Dualâ€hormone treatment with insulin and glucagon in patients with type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2015, 31, 672-679.	4.0	10
111	<scp>ACTH</scp> stimulation test in patients with type 1 diabetes and recurrent severe hypoglycaemia. Clinical Endocrinology, 2015, 82, 155-156.	2.4	1
112	An artificial pancreas for automated blood glucose control in patients with Type 1 diabetes. Therapeutic Delivery, 2015, 6, 609-619.	2.2	15
113	Intake of carbohydrates during pregnancy in obese women is associated with fat mass in the newborn offspring. American Journal of Clinical Nutrition, 2015, 102, 1475-1481.	4.7	42
114	The Association between Newborn Regional Body Composition and Cord Blood Concentrations of C-Peptide and Insulin-Like Growth Factor I. PLoS ONE, 2015, 10, e0121350.	2.5	9
115	Bihormonal model predictive control of blood glucose in people with type 1 diabetes. , 2014, , .		12
116	Predicting Plasma Glucose From Interstitial Glucose Observations Using Bayesian Methods. Journal of Diabetes Science and Technology, 2014, 8, 321-330.	2.2	7
117	Bolus Calculators. Journal of Diabetes Science and Technology, 2014, 8, 1035-1041.	2.2	120
118	Newborn regional body composition is influenced by maternal obesity, gestational weight gain and the birthweight standard score. Acta Paediatrica, International Journal of Paediatrics, 2014, 103, 939-945.	1.5	43
119	Changes in basal rates and bolus calculator settings in insulin pumps during pregnancy in women with type 1 diabetes. Journal of Maternal-Fetal and Neonatal Medicine, 2014, 27, 724-728.	1.5	41
120	The Treatment of Obese Pregnant Women (TOP) study: a randomized controlled trial of the effect of physical activity intervention assessed by pedometer with or without dietary intervention in obese pregnant women. American Journal of Obstetrics and Gynecology, 2014, 210, 134.e1-134.e9.	1.3	186
121	Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. Lancet Diabetes and Endocrinology,the, 2014, 2, 553-561.	11.4	83
122	Effects of advanced carbohydrate counting in patients with TypeÂ1 diabetes: a systematic review. Diabetic Medicine, 2014, 31, 886-896.	2.3	77
123	Representativeness of Participants in a Lifestyle Intervention Study in Obese Pregnant Women - the Difference between Study Participants and Non-Participants. Obesity Facts, 2014, 7, 351-360.	3.4	12
124	Assessment of Model Predictive and Adaptive Glucose Control Strategies for People with Type 1 Diabetes. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2014, 47, 231-236.	0.4	6
125	Routine Sensor-Augmented Pump Therapy in Type 1 Diabetes: The INTERPRET Study. Diabetes Technology and Therapeutics, 2013, 15, 273-280.	4.4	96
126	Model Identification Using Stochastic Differential Equation Grey-Box Models in Diabetes. Journal of Diabetes Science and Technology, 2013, 7, 431-440.	2.2	109

#	Article	IF	Citations
127	Model-Based Closed-Loop Glucose Control in Type 1 Diabetes: The DiaCon Experience. Journal of Diabetes Science and Technology, 2013, 7, 1255-1264.	2.2	30
128	An Early Warning System for Hypoglycemic/Hyperglycemic Events Based on Fusion of Adaptive Prediction Models. Journal of Diabetes Science and Technology, 2013, 7, 689-698.	2.2	43
129	Effects of Everyday Life Events on Glucose, Insulin, and Glucagon Dynamics in Continuous Subcutaneous Insulin Infusion–Treated Type 1 Diabetes: Collection of Clinical Data for Glucose Modeling. Diabetes Technology and Therapeutics, 2012, 14, 210-217.	4.4	17
130	Psychosocial Factors and Adherence to Continuous Glucose Monitoring in Type 1 Diabetes. Journal of Diabetes Science and Technology, 2012, 6, 986-987.	2.2	23
131	Tuning of Controller for Type 1 Diabetes Treatment with Stochastic Differential Equations. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2012, 45, 46-51.	0.4	4
132	Overnight Control of Blood Glucose in People with Type 1 Diabetes. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2012, 45, 73-78.	0.4	25
133	Sensor-Augmented Pump Therapy at 36 Months. Diabetes Technology and Therapeutics, 2012, 14, 1174-1177.	4.4	18
134	Insulin analogues and severe hypoglycaemia in type 1 diabetes. Diabetes Research and Clinical Practice, 2012, 96, 17-23.	2.8	51
135	Glucose sensor excludes hypoglycaemia as cause of death. Diabetes Research and Clinical Practice, 2012, 96, e30-e32.	2.8	3
136	A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design. BMC Endocrine Disorders, 2012, 12, 10.	2.2	18
137	Use of an Automated Bolus Calculator in MDI-Treated Type 1 Diabetes. Diabetes Care, 2012, 35, 984-990.	8.6	101
138	Sensor-augmented pump therapy lowers HbA1c in suboptimally controlled Type 1 diabetes; a randomized controlled trial. Diabetic Medicine, 2011, 28, 1158-1167.	2.3	151
139	Retinal function in relation to improved glycaemic control in type 1 diabetes. Diabetologia, 2011, 54, 1853-1861.	6.3	22
140	Physical activity during pregnancy in obese and normal-weight women as assessed by pedometer. Acta Obstetricia Et Gynecologica Scandinavica, 2010, 89, 956-961.	2.8	48
141	Continuous glucose monitoring-enabled insulin-pump therapy in diabetic pregnancy. Acta Obstetricia Et Gynecologica Scandinavica, 2010, 89, 1233-1237.	2.8	15
142	Obesity, body composition and metabolic disturbances in polycystic ovary syndrome. Human Reproduction, 2008, 23, 2113-2121.	0.9	80
143	Continuous Glucose Monitoring System With an Alarm: A tool to reduce hypoglycemic episodes in pregnancy with diabetes. Diabetes Care, 2006, 29, 2759-2760.	8.6	15
144	Validation of a checklist to assess ward round performance in internal medicine. Medical Education, 2004, 38, 700-707.	2.1	59

#	Article	IF	Citations
145	A nationwide study of continuous subcutaneous insulin infusion (CSII) in Denmark. Diabetic Medicine, 2003, 20, 307-311.	2.3	19
146	Urinary albumin excretion and 24-hour blood pressure as predictors of pre-eclampsia in Type I diabetes. Diabetologia, 2000, 43, 927-931.	6.3	50
147	The Predictive Value of Microalbuminuriq in IPPM: A five-year follow-up study. Diabetes Care, 1994, 17, 120-125.	8.6	108
148	Sodium retention and insulin treatment in insulin-dependent diabetes mellitus. Acta Diabetologica, 1994, 31, 19-25.	2.5	11
149	Transcapillary escape rate of albumin in hypertensive patients with Type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 1993, 36, 57-61.	6.3	38
150	Size- and charge selectivity of glomerular filtration in Type 1 (insulin-dependent) diabetic patients with and without albuminuria. Diabetologia, 1993, 36, 244-251.	6.3	143
151	A nationwide population-based study of the familial aggregation of Type 1 (insulin-dependent) diabetes mellitus in Denmark. Diabetologia, 1993, 36, 870-875.	6.3	95
152	A Comparison of Spirapril and Isradipine in Patients with Diabetic Nephropathy and Hypertension. Blood Pressure, 1993, 2, 301-308.	1.5	32
153	Nature of Elevated Blood Pressure in Normoalbuminuric Type I Diabetic Patients Essential Hypertension?. American Journal of Hypertension, 1993, 6, 830-836.	2.0	8
154	Microalbuminuria: Implications for micro- and macrovascular disease. Diabetes Care, 1992, 15, 1181-1191.	8.6	180
155	Is diabetic nephropathy an inherited complication?. Kidney International, 1992, 41, 719-722.	5.2	270
156	Effects of insulin on renal haemodynamics and sodium handling in normal subjects. Scandinavian Journal of Clinical and Laboratory Investigation, 1991, 51, 367-376.	1.2	26
157	Is Hypertension a Major Independent Risk Factor for Retinopathy in Type 1 Diabetes?. Diabetic Medicine, 1991, 8, 334-337.	2.3	47
158	Prevalence of hypertension in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 1991, 34, 64-65.	6.3	4
159	Lack of familial predisposition to cardiovascular disease in Type 1 (insulin-dependent) diabetic patients with nephropathy. Diabetologia, 1991, 34, 370-372.	6.3	18
160	A Nation€wide Cross€sectional Study of Urinary Albumin Excretion Rate, Arterial Blood Pressure and Blood Glucose Control in Danish Children with Type 1 Diabetes Mellitus. Diabetic Medicine, 1990, 7, 887-897.	2.3	106
161	Effects of Octreotide on Lipoproteins and Endothelial Function in Type 1 (Insulin€dependent) Diabetic Patients. Diabetic Medicine, 1990, 7, 909-913.	2.3	6
162	The role of hypertension in the development of nephropathy in type 1 (insulin-dependent) diabetes mellitus. Acta Diabetologica Latina, 1990, 27, 173-179.	0.2	5

#	Article	IF	Citations
163	Increased blood pressure and erythrocyte sodium/lithium countertransport activity are not inherited in diabetic nephropathy. Diabetologia, 1990, 33, 619-624.	6.3	125
164	Prevalence of hypertension in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 1990, 33, 407-410.	6.3	134
165	Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus. European Journal of Endocrinology, 1990, 122, 766-772.	3.7	59
166	Hypertension in the course of insulin dependent diabetes mellitus and its pathogenetic mechanisms. The Journal of Diabetic Complications, 1990, 4, 60-62.	0.2	1
167	Elevated Albumin Excretion and Retinal Changes in Children with Type 1 Diabetes are Related to Longâ€term Poor Blood Glucose Control. Diabetic Medicine, 1989, 6, 325-328.	2.3	61